EU6 Panoramica delle azioni PDS Biotechnology Corporation, un'azienda biofarmaceutica in fase clinica che sta sviluppando una pipeline di immunoterapie mirate contro il cancro negli Stati Uniti. Maggiori dettagli
Premi Analisi del rischio + 1 più rischio
Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
PDS Biotechnology Corporation Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per PDS Biotechnology Prezzi storici delle azioni Prezzo attuale dell'azione US$1.67 Massimo di 52 settimane US$6.08 Minimo di 52 settimane US$1.57 Beta 1.89 Variazione di 1 mese -11.89% Variazione a 3 mesi -49.91% Variazione di 1 anno -62.92% Variazione a 3 anni -73.53% Variazione a 5 anni -27.22% Variazione dall'IPO -72.56%
Notizie e aggiornamenti recenti
New minor risk - Market cap size Nov 16
PDS Biotechnology Corporation Provides Clinical Programs Update Nov 14
PDS Biotechnology Corporation to Report Q3, 2024 Results on Nov 14, 2024 Nov 06
PDS Biotechnology Corporation Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation Oct 03
PDS Biotechnology Corporation Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024 Sep 16
New major risk - Revenue and earnings growth Aug 13 Vedi altri aggiornamenti
New minor risk - Market cap size Nov 16
PDS Biotechnology Corporation Provides Clinical Programs Update Nov 14
PDS Biotechnology Corporation to Report Q3, 2024 Results on Nov 14, 2024 Nov 06
PDS Biotechnology Corporation Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation Oct 03
PDS Biotechnology Corporation Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024 Sep 16
New major risk - Revenue and earnings growth Aug 13
PDS Biotechnology Corporation to Report Q2, 2024 Results on Aug 13, 2024 Aug 07
Pds Biotech Aligns with Fda on Phase 3 Trial in Hpv16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer Aug 02 PDS Biotechnology Corporation(NasdaqCM:PDSB) dropped from Russell Small Cap Completeness Index
PDS Biotech Provides Data Update from Ongoing Versatile-002 Phase 2 Clinical Trial in Head and Neck Cancer Jun 13
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer May 11
PDS Biotechnology Corporation to Report Q1, 2024 Results on May 15, 2024 May 09
PDS Biotechnology Corporation Appoints Stephan Toutain as Chief Operating Officer May 03
PDS Biotechnology Corporation, Annual General Meeting, Jun 24, 2024 May 01
New minor risk - Market cap size Apr 18
PDS Biotechnology Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 21
PDS Biotechnology Corporation Announces Publication of Preclinical Research Mar 15
PDS Biotechnology Corporation Announces Executive Changes Jan 23 Pds Biotech Announces CFO Changes
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients Nov 10
PDS Biotechnology Corporation to Report Q3, 2023 Results on Nov 14, 2023 Nov 08
PDS Biotechnology Corporation Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients At ESMO Oct 24
PDS Biotechnology Corporation Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer Oct 12
New major risk - Financial position Sep 25
PDS Biotechnology Corporation Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies Sep 21
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate Versatile-003 Trial Aug 17
PDS Biotechnology Corporation to Report Q2, 2023 Results on Aug 14, 2023 Aug 08
PDS Biotechnology Corporation to Present Updated Immune Response Data from Combination of PDS0101 and KEYTRUDA in Head and Neck Cancer Patients at ESMO Congress 2023 Jul 26
PDS Biotechnology Corporation Strengthens Intellectual Property Portfolio Governing A Combination of Versamune®? and PDS0301 Jul 12
PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the Versatile-002 Trial Evaluating Pds0101 and Keytruda in Head and Neck Cancer Jun 15
PDS Biotechnology Corporation, Annual General Meeting, Jul 14, 2023 Jun 03
PDS Biotechnology Corporation Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with Keytruda (Pembrolizumab) for Head and Neck Cancer Patients May 27
Pds Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of Versatile-002 Phase 2 Clinical Trial in Advanced Hpv16 Positive Head and Neck Cancer May 19
PDS Biotechnology Corporation to Report Q1, 2023 Results on May 15, 2023 May 05
Insufficient new directors Mar 01
PDS Biotechnology Corporation Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune Feb 17
PDS Biotechnology Corporation Announces Preclinical Studies Involving Infectimune Feb 09
PDS Biotechnology Corporation Announces Abstract Accepted for Presentation At ESMO Targeted Anticancer Therapies Congress Feb 07
PDS Biotechnology Corporation Reports Median Overall Survival of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 Months Dec 30
PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced Hpv16 Positive Head and Neck Cancer Dec 17
PDS Biotechnology Corporation Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from Immunocerv Phase 2 Clinical Trial Nov 15
PDS Biotechnology Corporation Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunotherapy of Cancer (SITC 2022) Nov 08
PDS Biotechnology Corporation to Report Q3, 2022 Results on Nov 14, 2022 Nov 01
PDS Biotech Announces Abstract Demonstrating Versatility of the Versamune® Platform in Oncology Accepted for Presentation at AACR Special Conference on Tumor Immunology and Immunotherapy Oct 18
PDS Biotechnology Corporation Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers Oct 12
PDS Biotechnology Corporation Announces Successful End-of-Phase 2 Meeting With the FDA and Preparation for the Registrational Trial of PDS0101 in Combination With KEYTRUDA(R) Oct 04
PDS Biotechnology Corporation Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers Sep 22
PDS Biotech Independent Data Monitoring Committee Recommends Versatile-002 Trial Continuation Without Modifications Aug 06
PDS Biotechnology Corporation to Report Q2, 2022 Results on Aug 08, 2022 Jul 28
PDS Biotechnology Corporation Announces Presentation of Universal Flu Vaccine Preclinical Data At American Society of Virology Meeting Jul 15
PDS Biotechnology Corporation Appoints Spencer Brown as Senior Vice President, General Counsel Jun 04
U.S. Food and Drug Administration Grants PDS Biotechnology Fast Track Designation for Lead Candidate Pds0101 Jun 03
PDS Biotechnology Corporation Announces Expansion of Its VERSATILE-002 Clinical Trial into Europe Jun 01 PDS Biotechnology Corporation Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer At Asco 2022
PDS Biotechnology Corporation Appoints Sanjay Zaveri as Senior Vice President, Business Development May 19
PDS Biotechnology Corporation, Annual General Meeting, Jun 15, 2022 May 02
PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting Apr 28
No longer forecast to breakeven Mar 31
PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium Feb 25
PDS Biotechnology Corporation Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer Feb 16
PDS Biotechnology Corporation Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer Feb 03
PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine Jan 28
PDS Biotech Announces Presentation of PDS0101 Data at the 2022 Multidisciplinary Head and Neck Cancers Symposium Jan 13
Forecast to breakeven in 2024 Jan 01
PDS Biotechnology Corporation Announces Phase 2 Clinical Trial Update Dec 08
PDS Biotech Completes Enrollment of Lead-In Safety Cohort in VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA in Recurrent or Metastatic Head and Neck Cancer Sep 10
PDS Biotechnology Corporation Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting Jun 09
PDS Biotechnology Corporation Announces Protocol Amendment to Expand its Phase 2 VERSATILE-002 Study to Include Patients Jun 04
PDS Biotechnology Corporation Announces Release of Abstract for Pds0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation At 2021 Asco Meeting May 21
PDS Biotech Receives $60 Million Commitment for PDS Vaccine Consortium from Ministry of Science, Technology and Commercialisation of Brazil Mar 13
PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica Receives Award of Up to Approximately USD 60 Million Mar 12
PDS Biotechnology Corporation to Report Q4, 2020 Results on Mar 18, 2021 Mar 10
PDS Biotech and Farmacore Announce Blanver to Join Consortium to Commercialize Novel Versamune®-Based T-Cell Inducing Covid-19 Vaccine Feb 23
PDS Biotechnology Corporation Announces Preliminary Efficacy Achievement in Phase 2 Combination Trial of PDS0101 Led by the National Cancer Institute Feb 04
De Lyle Bloomquist to Retire from the Board of PDS Biotechnology Corporation Jan 29
PDS Biotechnology Corporation Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune®-based COVID-19 Vaccine Dec 23
Pds Biotechnology Corporation Appoints Seth Van Voorhees as Chief Financial Officer, Effective January 1, 2021 Dec 12
PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine Nov 12
PDS Biotechnology Corporation Initiates VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent/Metastatic Head and Neck Cancer in Collaboration with Merck Nov 10
PDS Biotechnology Corporation Appoints Otis W. Brawley as a Class C Director and New Member of the Board Nov 06
PDS Biotechnology Corporation to Report Q3, 2020 Results on Nov 11, 2020 Oct 30
PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 in Combination with Standard of Care Chemoradiotherapy in Advanced Cervical Cancer Oct 27
PDS Biotechnology Corporation has completed a Follow-on Equity Offering in the amount of $16.5 million. Aug 12 Rendimenti per gli azionisti EU6 DE Biotechs DE Mercato 7D 3.0% 2.1% -0.1% 1Y -62.9% -9.7% 7.4%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: EU6 ha avuto una performance inferiore rispetto al German Biotechs che ha registrato un rendimento -9.7 % nell'ultimo anno.
Rendimento vs Mercato: EU6 ha avuto una performance inferiore al mercato German che ha registrato un rendimento 7.4 % nell'ultimo anno.
Volatilità dei prezzi Is EU6's price volatile compared to industry and market? EU6 volatility EU6 Average Weekly Movement 11.0% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di EU6 è stato volatile rispetto al mercato German.
Volatilità nel tempo: La volatilità settimanale ( 11% ) di EU6 è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni German.
Informazioni sull'azienda PDS Biotechnology Corporation è una società biofarmaceutica in fase clinica che sta sviluppando una pipeline di immunoterapie mirate contro il cancro negli Stati Uniti. Il candidato principale dell'azienda è PDS0101 (HPV16), in fase di sperimentazione clinica di Fase II, che fornisce un trattamento di prima linea per il cancro ricorrente/metastatico della testa e del collo e per i tumori maligni associati al papillomavirus umano. L'azienda sviluppa anche diversi prodotti candidati, che sono in fase di sperimentazione preclinica, tra cui PDS0102, un'immunoterapia in fase di sperimentazione che utilizza la proteina TARP (tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein) per il trattamento dei tumori della prostata e della mammella; e PDS0103 per i tumori dell'ovaio, del colon-retto, del polmone e della mammella.
Mostra di più PDS Biotechnology Corporation Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di PDS Biotechnology con la sua capitalizzazione di mercato? EU6 statistiche fondamentali Capitalizzazione di mercato €65.34m Guadagni(TTM ) -€39.36m Ricavi(TTM ) n/a
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) EU6 Conto economico (TTM ) Ricavi US$0 Costo del fatturato US$0 Profitto lordo US$0 Altre spese US$40.56m Guadagni -US$40.56m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -1.08 Margine lordo 0.00% Margine di profitto netto 0.00% Rapporto debito/patrimonio netto 111.5%
Come si è comportato EU6 nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/06 22:40 Prezzo dell'azione a fine giornata 2025/01/03 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche PDS Biotechnology Corporation è coperta da 11 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione James Molloy Alliance Global Partners Mayank Mamtani B. Riley Securities, Inc. Kalpit Patel B. Riley Securities, Inc.
Mostra 8 altri analisti 
